Press Release: Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) for Development and Commercial Rights to CGS-200-5 in Greater China

Propella Therapeutics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. announced that the companies have entered into an exclusive licensing agreement for CGS-200-5, a clinical-stage topical treatment that is being developed for the treatment of pain in patients with moderate to severe osteoarthritis of the knee.

Presentation: Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats (Abstract #160)

Propella Therapeutics, Inc. presented “Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats (Abstract #160)” at the American Society of Clinical Oncology Genitourinary Symposium on February 17, 2022.

Presentation: 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022)

Propella Therapeutics, Inc. participated in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022.

Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event

Propella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer.

Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index

Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.

Presentation: Abstract 337037: A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)

Propella Therapeutics, Inc. presented “A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)” at the American Society of Clinical Oncology Annual Meeting on June 4, 2021.

Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer

Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.

Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer

Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.

Presentation: Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model (citation and abstract are found at https://meetinglibrary.asco.org/record/194919/abstract)

Propella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium on February 11, 2021.